120 related articles for article (PubMed ID: 17490733)
21. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
22. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
23. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines.
Zhang H; Wang S; Cacalano N; Zhu H; Liu Q; Xie M; Kamrava M; Konecny G; Jin S
Sci Rep; 2019 Feb; 9(1):2111. PubMed ID: 30765787
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
26. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro.
Zhuang HQ; Wang J; Yuan ZY; Zhao LJ; Wang P; Wang CL
J Exp Clin Cancer Res; 2009 Sep; 28(1):123. PubMed ID: 19723324
[TBL] [Abstract][Full Text] [Related]
27. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
29. [Sensitivity of PTEN gene-transfected endometrial carcinoma cell line to doxorubicin-induced apoptosis].
Wan XY; Mao YY; Yokoyama Y
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):513-5. PubMed ID: 16438844
[TBL] [Abstract][Full Text] [Related]
30. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer.
Alhaj-Suliman SO; Naguib YW; Wafa EI; Saha S; Ebeid K; Meng X; Mohammed HH; Abuo-Rahma GEA; Yang S; Salem AK
Biomaterials; 2023 May; 296():122093. PubMed ID: 36965280
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
32. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K
Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379
[TBL] [Abstract][Full Text] [Related]
33. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
34. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Ahn MY; Jung JH; Na YJ; Kim HS
Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664
[TBL] [Abstract][Full Text] [Related]
35. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.
Zhao YF; Wang CR; Wu YM; Ma SL; Ji Y; Lu YJ
Biomed Pharmacother; 2011 Jun; 65(3):151-6. PubMed ID: 21616632
[TBL] [Abstract][Full Text] [Related]
36. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
37. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2 exerts a pRb-mediated cell cycle inhibitory function in HEC1B endometrial carcinoma cells.
Crescenzi E; Palumbo G
Gynecol Oncol; 2001 May; 81(2):184-92. PubMed ID: 11330947
[TBL] [Abstract][Full Text] [Related]
39. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
40. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Bianco R; Shin I; Ritter CA; Yakes FM; Basso A; Rosen N; Tsurutani J; Dennis PA; Mills GB; Arteaga CL
Oncogene; 2003 May; 22(18):2812-22. PubMed ID: 12743604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
